Biosurfit

What Biosurfit does

Biosurfit SA is a privately held Portuguese in-vitro diagnostics company founded in 2006 and headquartered in Azambuja, Portugal, with 51-100 employees. The company develops and commercialises the spinit® point-of-care diagnostics platform, a centrifugal microfluidic system that runs immunoassay, haematology, and clinical chemistry panels from a single 8 µL finger-prick blood sample on disposable CD/DVD-format discs inside a benchtop instrument. Results for CRP, blood count (5-part WBC differential), and HbA1c are returned in 4-7 minutes, with HbA1c certified to IFCC and NGSP reference standards and all products CE Marked. The platform and underlying technology are protected by 31 patent families, more than 21 of which are authored by founder and Chairman João Garcia da Fonseca.

Biosurfit operates a razor-and-blade commercial model: spinit® instruments are placed with healthcare customers (primary care clinics, emergency departments, pharmacies, and mobile health units) while recurring revenue comes from single-use CRP, BC, HbA1c, and control discs. Go-to-market is channel-led through regional distributors (Axon Lab in the Netherlands, Czech Republic, Switzerland, and Germany; TECIL in Spain; Bioservice in Romania; Alatheia Medical in Chile) plus direct sales from HQ, supported by participation at MEDICA and Expofarma and a spinit® Learning Center for healthcare professionals. In October 2024 the company expanded into Contract Development and Manufacturing (CDMO) services, offering end-to-end development, microfluidics solutions, blister development (added April 2025), and ISO 13485:2016-certified manufacturing to external biotech, pharma, and IVD clients from its Azambuja cleanroom facilities (ISO Class 7 and 8).

Capital structure reflects a mix of debt and non-dilutive funding: a EUR 12M European Investment Bank InnovFin loan (2015), EUR 1.4M European Commission 7th Framework grant, EUR 4.3M PT2020 grant, EUR 10M equity from Boule Diagnostics and the 200M co-investment fund (2022), and ongoing EU COMPETE2030-FEDER R&D project co-funding. Strategic R&D partnerships include i3S (LiverHealthX, Leukospin, SEPSIS multiSPIN) and FIND for haematology access in low- and middle-income countries. Leadership transitioned in 2020, with founder João Garcia da Fonseca moving to Chairman and former CFO Rosa Santos appointed CEO.

Name

Biosurfit

Legal name

biosurfit SA

Website

https://biosurfit.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

Biosurfit is a Portuguese point-of-care diagnostics company that develops the spinit® centrifugal microfluidic platform, enabling rapid quantitative blood testing (CRP, blood count, HbA1c) for healthcare providers, and offers CDMO services to IVD clients.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

akta.pro secondary industry

Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)

Keywords

• Point-of-care diagnostics
• Centrifugal microfluidics
• Blood analysis platforms
• Contract development manufacturing
• Clinical chemistry testing

Headquarters

HQ city

Lisbon

HQ country

Portugal

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. spinit® Instrument Sales: Sale of the spinit® diagnostic instrument hardware to healthcare facilities. The instrument is designed to be maintenance-free with no user calibration required.
2. spinit® Disposable Discs (CRP, BC, HbA1c): Recurring sale of single-use disposable discs (CRP, Blood Count, HbA1c, and control discs) that perform specific diagnostic tests on the spinit® instrument. Discs are packaged individually (kit of 20 tests). This represents a recurring consumables revenue stream tied to instrument placement.
3. Contract Development & Manufacturing (CDMO) Services: B2B contract services covering the full product lifecycle: end-to-end development (R&D, design, prototyping, validation, regulatory approvals), microfluidics solutions, and manufacturing of diagnostic devices, reagents, and consumables. Includes blister development and liquid blister manufacturing services. Revenue generated through project-based and long-term contractual engagements with biotech, pharma, and diagnostic companies.
4. Contract Manufacturing (CDMO): ISO 13485:2016-certified manufacturing services from pilot-scale prototyping to fully automated large-scale production of diagnostic cartridges and instruments for external clients.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

Core offering

Biosurfit develops and sells the spinit® point-of-care diagnostics platform, consisting of a benchtop instrument and disposable CD/DVD-format microfluidic discs that perform quantitative blood tests (CRP, blood count/differential, HbA1c) from an 8 µL finger-prick sample in 4–7 minutes. The company also offers Contract Development and Manufacturing (CDMO) services, providing end-to-end diagnostic product development, microfluidics engineering, and ISO 13485:2016-certified manufacturing of cartridges and instruments for third-party IVD, biotech, and pharma clients.

Product overview

Biosurfit offers the spinit® platform as a unified Point-of-Care diagnostics system consisting of a main instrument and multiple disposable test discs. The spinit® instrument performs immunoassay, haematology, and clinical chemistry tests using microfluidic discs. Current commercial products include spinit® CRP (C-reactive protein), spinit® BC (blood count/WBC differential), and spinit® HbA1c (glycated hemoglobin), all run on the same instrument. Quality is managed through spinit® controls. The company also offers Contract Development and Manufacturing (CDMO) services leveraging 31 patent families in microfluidics, plus blister development solutions as part of its service portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• spinit®: Fully automated Point-of-Care diagnostics solution platform that integrates multiple diagnostic tests into a single device for rapid blood analysis
• COVID Checked

Products and services

• spinit® Instrument Fully automated point-of-care diagnostic instrument that runs microfluidic disposable discs and delivers quantitative blood parameter measurements by combining immunoassay, haematology, and clinical chemistry detection methods in a single benchtop device. Targeted at healthcare facilities and clinical settings.
• spinit® CRP Single-use disposable disc for quantitative measurement of C-reactive protein (CRP) concentration in whole blood, serum, and plasma samples, used on the spinit® instrument for point-of-care inflammation detection in less than 4 minutes.
• spinit® BC Disposable disc for quantitative measurement of total white blood cells and 5-part differential counts (neutrophils, lymphocytes, monocytes, eosinophils, basophils) on the spinit® instrument, delivering blood count results in approximately 7 minutes.
• spinit® HbA1c Disposable disc for quantitative measurement of glycated hemoglobin (HbA1c) in whole blood (venous and capillary) on the spinit® instrument for point-of-care diabetes monitoring, returning results in less than 6 minutes with IFCC- and NGSP-certified accuracy.
• spinit® controls Quality control solutions sold alongside the spinit® CRP, BC and HbA1c tests to verify that the spinit® instrument and disc systems are performing within specification and delivering reliable results.
• CDMO Services Contract development and manufacturing services covering the full lifecycle of diagnostic and medical device products, leveraging Biosurfit's 31 patent families in microfluidics, ISO 13485:2016-certified facilities, and cleanrooms (Class ISO 7 & ISO 8). Targeted at IVD manufacturers, biotech, and pharma companies.
• Contract Development Services Bespoke R&D and product development services including advanced microfluidics development, prototyping, point-of-care test development, and equipment engineering, supporting diagnostic and medical device clients from concept through regulatory submission.
• Contract Manufacturing Services ISO 13485:2016-certified manufacturing of diagnostic cartridges and instruments for third-party clients, ranging from pilot-scale prototyping to fully automated large-scale production using Azambuja cleanroom facilities (Class ISO 7 & ISO 8).
• Blister Development Solutions Advanced blister development and liquid blister manufacturing services supporting diagnostic and healthcare applications from early development through commercial-scale production, offered as part of Biosurfit's CDMO portfolio.

Quantifiable outcome

• CRP results in <4 minutes, HbA1c in <6 minutes, Blood Count in 7 minutes
• +4 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• i3S (Instituto de Investigação e Inovação em Saúde)coreStrategic or Co-development Partner · 1 March 2025Co-development partnership with i3S on multiple R&D projects: LiverHealthX (point-of-care liver function test with protein, cellular and genetic biomarkers), SEPSIS multiSPIN (sepsis diagnostic with protein and genetic panels using isothermal amplification and microfluidics), and Leukospin (sepsis diagnostic differentiating bacterial and viral infections using microfluidics, fluorescence microscopy and machine learning). EU co-funded through COMPETE2030-FEDER.
• CDMO Industry Partners (unnamed)coreStrategic or Co-development Partner · 1 October 2024Multiple partnerships with industry players to co-develop innovative diagnostic tools addressing unmet clinical needs, as announced with the October 2024 launch of biosurfit's CDMO business unit. Partnerships are for end-to-end development, microfluidics solutions, and manufacturing capabilities.
• Glintt LifeminorChannel Partner/ Reseller/ Distributor · 1 January 2024Partnership at Expofarma 2024 focused on decentralised diagnostics, positioning pharmacies as pivotal points in patient care using biosurfit's spinit® technology.
• Cruz Vermelha (Portuguese Red Cross)minorStrategic or Co-development Partner · 1 January 2023Smart Triage partnership with Cruz Vermelha for opening mobile diagnostic units in Azambuja, Telheiras, Corroios, and Cascais, enabling decentralised community-based testing using spinit® technology.
• FIND (Foundation for Innovative New Diagnostics)coreStrategic or Co-development Partner · 1 January 2021Strategic partnership with FIND, the global alliance for diagnostics, to accelerate the commercialisation of haematology solutions (spinit® BC) to low- and middle-income countries. This partnership leverages FIND's global network and regulatory expertise to expand access to biosurfit's point-of-care diagnostics in underserved markets.
• Rev DiagnosticsminorChannel Partner/ Reseller/ Distributor · 1 January 2015First distribution agreement signed in June 2011 (as noted in history timeline) for the Netherlands market, representing the initial international distribution partnership for biosurfit's spinit® products.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Abbott Point of Care (i-STAT / Alinity): Abbott's i-STAT and Alinity platforms are cartridge-based point-of-care blood analyzers delivering quantitative results (blood gases, electrolytes, immunoassays, haematology) from small whole-blood samples at the bedside — the closest direct functional and commercial analogue to spinit®, but with a much broader test menu and global installed base.
• Siemens Healthineers (epoc Blood Analysis): Siemens' epoc system is a handheld, single-use cartridge PoC blood analyser with multi-parameter blood gas, electrolyte and metabolite panels — directly comparable to spinit®'s mission of delivering lab-quality multi-parameter blood results at the point of care, though using a different fluidic architecture.
• EKF Diagnostics: EKF specialises in point-of-care hemoglobin, HbA1c and related haematology/clinical chemistry devices (e.g., QuikRead, HemoControl). It directly overlaps with spinit®'s HbA1c and CRP/Blood Count panels and competes for the same primary-care and pharmacy placements.
• HemoCue (Danaher): HemoCue, now part of Danaher's Beckman Coulter diagnostics business, sells point-of-care haemoglobin, glucose and HbA1c analyzers with a strong global distribution network. It competes with spinit® for primary-care and decentralised testing workflows focused on anaemia/diabetes screening.
• QuidelOrtho (Triage / Sofia): QuidelOrtho's Triage and Sofia platforms deliver rapid quantitative immunoassays (CRP, BNP, D-dimer, infectious disease markers) at the point of care — overlapping directly with spinit® CRP and with broader PoC infection/inflammation decision-making use cases.

Broad incumbents

• Roche Diagnostics (cobas / ACCU-CHEK): Roche operates central-lab cobas systems as well as cobas Liat and ACCU-CHEK point-of-care devices covering immunoassays and clinical chemistry. It competes with spinit® in physician offices and emergency settings while also operating a much broader diagnostics portfolio across the value chain.

Others

• Boule Diagnostics: Boule Diagnostics is a Sweden-based specialist in haematology point-of-care instruments (Medonic, Microsemi) and a strategic equity investor in Biosurfit. It is a portfolio-adjacent peer and direct distribution/sales-channel partner rather than a head-to-head competitor in the disc-format space.
• STRATEC Biomedical: STRATEC is a leading OEM/CDMO partner for IVD and life-science instrumentation — directly comparable to Biosurfit's newly-launched CDMO business unit offering IVD cartridge and instrument development/manufacturing to third parties.

Emerging players

• Mobidiag (Hologic): Mobidiag (acquired by Hologic) developed the Amplidiag and Novodiag cartridge-based molecular diagnostics platforms, illustrating the kind of molecular diagnostic-on-a-disc roadmap Biosurfit is pursuing with its spinit® CRISPR / SEPSIS multiSPIN programmes.
• Eurolyser (AMC): Eurolyser (part of AMC group) is a Salzburg/Salzburg-based manufacturer of compact point-of-care clinical chemistry and immunoassay analyzers (CRP, HbA1c, glucose, coagulation). It targets the same primary-care and pharmacy channels as spinit® across Europe, with overlapping panel focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Biosurfit
• YouTubeyoutube.com/channel/biosurfit
• LinkedInlinkedin.com/company/biosurfit

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosurfit